RevMed nears EU okay for pancreatic cancer drug Rasonque
Revolution Medicines is just weeks away from getting EU approval for its keenly anticipated oral RAS drug Rasonque for pancreatic cancer.
Revolution Medicines
Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers and other difficult-to-treat tumors.
Company Info
Sector:Oncology
Headquarters:Redwood City, California, United States
Founded:2014
Website:www.revmed.com/
Upcoming Milestones & Key Dates
2027-H1
Clinical
Daraxonrasib Phase 3 data expected
Clinical Development Pipeline
Daraxonrasib (RMC-6236)
Target: RAS(ON)Darovasertib (RMC-6291)
Target: GNAQ/GNA11Elironrasib (RMC-5127)
Target: KRAS G12VRecent News
FDA's Rasonque review documents pressure RevMed
FDA review documents for Revolution Medicines' newly approved Rasonque are keeping investors jittery over KRAS-subgroup data as the company works to establish the drug in pancreatic and lung cancer.
As RevMed preps for 'historic' cancer launch, questions linger
As RevMed preps for 'historic' cancer launch, questions linger
RevMed could become ‘next oncology titan’ with Rasonque nod
RevMed could become ‘next oncology titan’ with Rasonque nod
RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
FDA greenlights RevMed’s pancreatic cancer gamechanger
FDA greenlights RevMed’s pancreatic cancer gamechanger
'Significant' demand for Revolution drug; Intellia pinpoints liver toxicity culprit
'Significant' demand for Revolution drug; Intellia pinpoints liver toxicity culprit
Revolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses
Revolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses
Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer
Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec — Endpoints News coverage of biopharma industry developments.
Leadership Team
Mark Goldsmith
Chief Executive Officer
Jack Anders
Chief Financial Officer
Wei Lin
Chief Medical Officer